Anti-Mouse CD86 (B7-2)

SPECIFICITY

The PO3 antibody reacts with the B7-2 co-stimulatory molecule,1 which is expressed on a broad spectrum of cells, including B cells, T cells, macrophages, and dendritic cells.2,3,4 B7-2 is expressed at low levels by freshly explanted B and peripheral T cells, and its expression is substantially increased by a variety of T and B cell-specific stimuli with a peak expression after 18 - 42 hours of culture.2,3,4 CD86, a ligand for CD28 and CTLA-4, is one of the accessory molecules that plays an important role in T cell-B cell co-stimulatory interactions.2,3,4 PO3 antibody blocks the in vitro stimulation of T-cell proliferation by soluble anti-CD3e antibody (clone 145-2C11, Cat. no. 01080D) in the presence of CD86-expressing accessory cells.1 In vivo administration of PO3 mAb can inhibit much of the autoantibody production in (NZB x NZW) F1 mice; and in combination with an anti-CD80 mAb, it can prevent the development and progression of mouse systemic lupus erythematosus-like autoimmune disease.1 CD80 (B7-1) is an alternate ligand for CD28 and CTLA-4.1,2,3,4

USAGE

This antibody has been tested by by LAL assay for endotoxin level and by immunofluorescent staining (lesser than or equal to 1 µg/million cells) with flow cytometric analysis to assure specificity and reactivity. Other reported applications include in vivo and in vitro blocking assays.1 Since applications vary, each investigator must determine dilutions appropriate for individual use.

Cat. No. Description Clone Isotype Size
09880D Purified anti-mouse CD86, NALE (B7-2) PO3 Rat IgG2b kappa 0.5mg
09881D Purified anti-mouse CD86, (B7-2) PO3 PO3 Rat IgG2b kappa 0.5mg
09982D Biotinylated anti-mouse CD86, (B7-2) PO3 Rat IgG2b kappa 0.5mg

For Research Use Only. Not For Diagnostic or Therapeutic Use.

REFERENCES
1. Nakajima, A., M. Azuma, S. Kodera, S. Nuriya, A. Terashi, M. Abe, S. Hirose, T. Shirai, H. Yagita, and K. Okumura. 1995. Preferential dependence of autoantibody production in murine lupus on CD86 co-stimulatory molecule. Eur. J. immunol. 25: 3060 - 3069.
2. Lenschow, D.J., G.H. Su, L.A. Zuckerman, N. Nabavi, C.L. Jellis, G.S. Gray, J. Miller, and J.A. Bluestone. 1993. Expression and functional significance of an additional ligand for CTLA-4. Proc. Natl. Acad. Sci. USA 90: 11054 - 11058.
3. June, C.H., J.A. Bluestone, L.M. Nadler, and C.B. Thompson. 1994. The B7 and CD28 receptor families. Immunol. Today 15: 321 - 331.
4. Boussiotis, V.A., J.G. Gribben, G.J. Freeman, and L.M. Nadler. 1994. Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance. Curr. Opin. Immunol. 6: 797 - 807.

Related products for Cell Interaction research include antibodies to CD80, CTLA-4, and CD28.

[Homepage] [New Products Page] [Catalog of Products] [Ordering Information] [Technical Service]